Leveraging Electronic Health Records and Claims Data in Phase 4 Clinical Trials

Posted on digi By digi

Leveraging Electronic Health Records and Claims Data in Phase 4 Clinical Trials

Published on 14/01/2026

How to Use EHR and Claims Data to Power Real-World Phase 4 Clinical Research

Introduction

Phase 4 clinical trials are designed to evaluate a drug’s performance in real-world populations over extended periods. With the rise of digital health systems, researchers can now tap into two robust data streams: Electronic Health Records (EHR) and claims data. These data sources enable cost-effective, large-scale analyses of treatment outcomes, adherence, safety trends, and comparative effectiveness without needing to initiate new trials from scratch.

This article serves as a tutorial for researchers and sponsors looking to harness EHR and claims data for Phase 4 evidence generation. You’ll learn how to access, analyze, and apply these datasets to strengthen post-marketing surveillance and regulatory filings.

What Are EHR and Claims Data?

Electronic Health Records (EHR)

Digitally stored patient medical records from hospitals, clinics, and general practitioners. Key components include:

  • Demographics
  • Lab test results
  • Diagnosis codes
  • Medication orders
  • Clinical notes
See also  Data Mining for Adverse Drug Reactions in Phase 4 Clinical Trials

Claims Data

Administrative data collected by insurance providers for billing and reimbursement. Includes:

  • Diagnosis and procedure codes (ICD, CPT)
  • Dates of service and care setting
  • Medication dispensing information
  • Billing amounts and reimbursement details

Why Use EHR and Claims Data in Phase 4?

  • Real-world applicability: Reflects daily clinical practice across varied populations
  • Cost-efficiency: No need to
establish new infrastructure for data capture
  • Speed: Access to retrospective data for faster insights
  • Large scale: Millions of patient records available for population-based analysis

    • Use Cases in Phase 4 Trials

    1. Adherence and Persistence Studies

    • Claims data show refill patterns, dosage consistency, and discontinuation rates

    2. Comparative Effectiveness Research (CER)

    • Match patients on demographics and comorbidities to compare outcomes

    3. Rare Adverse Event Detection

    • Large patient volumes in EHR systems can help detect uncommon side effects

    4. Off-Label Use Monitoring

    • Identify mismatches between diagnosis codes and drug indication

    5. Health Economics and Outcomes Research (HEOR)

    • Track cost of care, resource utilization, and hospitalization trends

    Data Access Strategies

    • Hospital Networks: Collaborate with EHR-enabled hospital systems (e.g., Mayo Clinic, Cleveland Clinic)
    • Claims Databases: Access commercial datasets such as Optum, IBM MarketScan, and Medicare
    • National Research Networks: TriNetX, PCORnet, and OMOP-based systems

    Data Integration and Quality

    • Use standardized vocabularies like SNOMED, LOINC, and RxNorm
    • Apply data cleaning, deduplication, and mapping protocols
    • Use data transformation pipelines with common data models (e.g., OMOP CDM)

    Regulatory Considerations

    FDA

    • Permits use of EHR and claims data to support supplemental New Drug Applications (sNDA)
    • RWE framework provides guidance on data quality, traceability, and curation

    EMA

    • DARWIN EU initiative aims to integrate healthcare databases across Europe
    • Accepts observational RWE for safety surveillance and label modifications

    CDSCO

    • Increasing focus on claims data from Ayushman Bharat and state health schemes for post-marketing analysis

    Challenges and Limitations

    • Data fragmentation: Information may be spread across multiple systems
    • Incomplete fields: Missing lab values, outcomes, or medication details
    • Coding variability: ICD codes may lack specificity for some research questions
    • Bias and confounding: Lack of randomization requires careful statistical adjustment

    Statistical Methods for Analysis

    • Propensity score matching to balance covariates
    • Time-to-event analysis (Kaplan-Meier, Cox regression)
    • Interrupted time series for pre/post intervention comparison
    • Multilevel modeling for site-specific variations

    Real-World Case Example

    A Phase 4 study of GLP-1 agonists in Type 2 diabetes used EHR data to evaluate cardiovascular outcomes. Analysis of 100,000+ patients showed real-world reduction in major adverse cardiovascular events (MACE), supporting updated prescribing guidelines in high-risk populations.

    Best Practices

    • Predefine your analysis protocol and get IRB approval where needed
    • Use qualified statisticians with RWE experience
    • Collaborate with health informatics experts to clean and standardize data
    • Validate findings through triangulation (e.g., EHR + registry)

    Conclusion

    Phase 4 trials supported by EHR and claims data offer sponsors and researchers a scalable, efficient way to generate regulatory-grade real-world evidence. With proper governance, data validation, and analytics, these resources can power label expansion, improve safety monitoring, and shape health policy. At ClinicalStudies.in, we help you build EHR-compatible protocols, establish claims data pipelines, and transform raw records into actionable post-marketing insights.

    Phase 4 (Post-Marketing Surveillance) Tags:, , , , , , , , , , , , , , , , , , , , , , , ,